An investigational exosome-based liquid biopsy accurately detected 97% of stage 1-2 pancreatic cancers when combined with the biomarker CA 19-9, according to research presented at the American ...

The company’s pipeline of products includes the ExoDx Prostate test, the first exosome-based liquid biopsy on the market, and various discovery platforms to help solve biopharma’s biomarker ...

requiring them to lyse the exosomes to confirm LAT1 expression. “If we can make such an antibody, we can directly detect LAT1 on liquid biopsy, like blood or plasma,” Ohgaki said. Greening, who wasn’t ...

Collaboration aims to evaluate the potential to advance drug development with Exosome’s proprietary liquid biopsy diagnostics technology and platform. with the Breaking Science News daily newsletter ...

If detected early, cancer is much easier to treat. Emerging non-invasive tests can help early diagnosis. As diseases go, cancer is deadly. Its early detection, however, can make a huge difference to ...

According to Research by SNS Insider, the growth of the liquid biopsy market is driven by significant technological advancements and a growing preference for minimally invasive procedures.Pune, March ...

The global liquid biopsy market is experiencing substantial growth, driven by increasing demand for non-invasive diagnostic technologies that detect molecular biomarkers using liquid samples, thus ...